Welcome to our dedicated page for Novonix SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NOVONIX Limited (NVNXF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. NOVONIX files Form 6-K current reports under the Securities Exchange Act of 1934, identified by Commission File Number 001-41208. These filings typically incorporate Australian Securities Exchange (ASX) documents and other materials that describe changes in NOVONIX’s securities, governance, and corporate actions.
Recent NOVONIX 6-K filings reference ASX forms such as Appendix 2A (Application for quotation of securities), Appendix 3H (Notification of cessation of securities), and Appendix 3X (Initial Director’s Interest Notice). Through these exhibits, investors can track events including new share quotations, cessation of securities, and initial disclosures of director interests. Other 6-Ks attach ASX announcements related to board appointments and other corporate developments.
For NVNXF investors, these filings complement company news releases that discuss NOVONIX’s battery materials and technology activities, including synthetic graphite projects in Chattanooga, Tennessee, technology licensing arrangements, and financing transactions. While detailed financial statements and risk discussions are typically provided in annual and periodic reports, the 6-Ks offer interim updates on material information that NOVONIX chooses to furnish to the SEC.
On this page, Stock Titan surfaces NOVONIX’s SEC submissions as they appear on EDGAR and pairs them with AI-powered summaries to explain the practical meaning of each filing. This can help readers quickly understand whether a filing relates to new securities being quoted, changes in existing securities, director interest notices, or other corporate announcements. Users interested in insider-related disclosures can review exhibits such as Appendix 3X, while those focused on capital structure can examine Appendices 2A and 3H and their associated descriptions.
NOVONIX Limited has reported the lapse of 139,547 NVXAD performance rights. These rights ceased on February 2, 2026 because the conditions attached to them were not met or had become incapable of being satisfied. No consideration was paid in connection with this cessation.
After this change, the company reports 859,902,420 NVX ordinary fully paid shares on issue. It also has 17,388,628 remaining NVXAD performance rights, 14,016,667 NVXAA options, 1,008,567 NVXAB share rights and 45,221,586 NVXAL convertible notes on issue.
NOVONIX LIMITED is arranging quotation on ASX for 127,021 new ordinary fully paid shares, issued on 30 January 2026 after conversion of performance rights under an employee incentive scheme. These shares are issued for non-cash consideration valued at AUD 0.39 per share.
The new shares form part of the existing NVX ordinary share class and will rank equally with all other quoted ordinary shares from their issue date. After this quotation, the company reports 859,902,420 NVX ordinary shares on issue, along with several unquoted classes including performance rights, options, share rights and convertible notes.
NOVONIX Limited filed a quarterly activities and cash flow update showing continued investment in battery materials alongside higher funding. Operating activities used $9.7M in cash for the quarter, while capital expenditure reached $13.4M, mainly on the Riverside anode materials facility.
Financing inflows from unsecured convertible debentures totaled $49.4M this quarter, lifting cash and equivalents to $81.3M as of 31 December 2025, or an estimated 8.4 quarters of funding at the current burn rate. The company completed its full $100M Yorkville debenture program in 2025.
Commercially, NOVONIX advanced its anode and cathode platforms, delivering over 100 synthetic graphite samples to 15 customers and 10 cathode samples to seven OEMs and Tier‑1 battery makers, and launched a UHPC Calibration Module. Offsetting this, Stellantis terminated its large offtake agreement, while NOVONIX remains focused on Panasonic, PowerCo and other prospects amid supportive U.S. trade actions on Chinese graphite.
Novonix Limited filed a Form 6-K as a foreign private issuer for December 2025. The filing mainly forwards an exhibit, Appendix 2A, which is an application for quotation of securities dated December 18, 2025. The report is signed by the Chief Financial Officer, Robert Long.
Novonix Limited has reported a change in its board of directors. The company submitted a report to U.S. regulators highlighting an attached announcement from the Australian Securities Exchange.
The exhibit notes the appointment of Mike O'Kronley to the Board of Directors, dated December 15, 2025. This update formally records the new board role for investors who follow Novonix through U.S. markets.